Phase II trials of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

Bibliography

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. Cancer J Clin 2013;63(1):11-30
   PubMed Web of Science ®Google Scholar
• Schiffer CA. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med 2007;357(3):258-65
   PubMed Web of Science ®Google Scholar
• Mandanas RA, Leibowitz DS, Gharehbaghi K, et al. Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells. Blood 1993;82(6):1838-47
   Google Scholar
• Okuda K, Matulonis U, Salgia R, et al. Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1. Exp Hematol 1994;22(11):1111-17
   Google Scholar
• Raitano AB, Halpern JR, Hambuch TM, Sawyers CL. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci USA 1995;92(25):11746-50
   Google Scholar
• Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL oncogenes. Cell 1992;70(6):901-10
   Google Scholar
• Shuai K, Halpern J, ten Hoeve J, et al. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 1996;13(2):247-54
   PubMed Web of Science ®Google Scholar
• Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 1996;183(3):811-20
   PubMed Web of Science ®Google Scholar
• Ilaria RL Jr, Van Etten RA. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 1996;6:271(49):31704-10
   Google Scholar
• Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2(5):561-6
   PubMed Web of Science ®Google Scholar
• Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (New York, NY) 2004;305(5682):399-401
   Google Scholar
• Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011;117(4):1141-5
   PubMed Web of Science ®Google Scholar
• Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354(24):2531-41
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 2012;30(28):3486-92
   PubMed Web of Science ®Google Scholar
• Goldman JM. Ponatinib for chronic myeloid leukemia. N Engl J Med 2012;367(22):2148-9
   Google Scholar
• Quintas-Cardama A, Kantarjian HM, Cortes JE. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control 2009;16(2):122-31
   PubMed Web of Science ®Google Scholar
• O'Brien S, Berman E, Moore JO, et al. NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. J Natl Compr Cancer Netw 2011.9(Suppl 2):S1-25
   Google Scholar
• Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27(35):6041-51
   PubMed Web of Science ®Google Scholar
• Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108(6):1809-20
   PubMed Web of Science ®Google Scholar
• O'Brien S, Abboud CN, Akhtari M, et al. NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia. Available from: NCCN.org 2013; Version 2
   Google Scholar
• Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108(1):28-37
   PubMed Web of Science ®Google Scholar
• Baccarani M, Rosti G, Castagnetti F, et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood 2009;113(19):4497-504
   Google Scholar
• NCCN. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia. (NCCN Guidelines®). NCCN 2013 (February);Version 4.2013.
   Google Scholar
• Castagnetti F, Palandri F, Amabile M, et al. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. Blood 2009;113(15):3428-34
   Web of Science ®Google Scholar
• Hanfstein B, Muller MC, Hehlmann R, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012;26(9):2096-102
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Hughes TP, Saglio G, et al. Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) based on early molecular response and factors associated with early response: 4-year follow-up data from ENESTnd (evaluating nilotinib efficacy and safety in clinical trials newly diagnosed patients). ASH Annu Meet Abstr 2012;120(21):167
   Google Scholar
• Saglio G, Kantarjian HM, Shah N, et al. early response (molecular and cytogenetic) and long-term outcomes in newly diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory analysis of DASISION 3-Year data. ASH Annu Meet Abstr 2012;120(21):1675
   Google Scholar
• Jabbour E, Kantarjian HM, O'Brien S, et al. Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response? J Clin Oncol 2011;29(32):4260-5
   PubMed Web of Science ®Google Scholar
• Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012;30(3):232-8
   PubMed Web of Science ®Google Scholar
• Jain P, Kantarjian H, Nazha A, et al. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood 2013;121(24):4867-74
   PubMed Web of Science ®Google Scholar
• Nazha A, Kantarjian HM, Jain P, et al. Disease patterns for Patients (pts) with Chronic Myeloid Leukemia (CML) that have BCR-ABL transcript levels > 10% at 3 month of therapy with Tyrosine Kinase Inhibitors (TKIs). ASH Annu Meet Abstr 2012;120(21):3757
   Google Scholar
• Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000;105(1):3-7
   PubMed Web of Science ®Google Scholar
• Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344(14):1031-7
   PubMed Web of Science ®Google Scholar
• O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348(11):994-1004
   PubMed Web of Science ®Google Scholar
• Deininger M, O'Brien BS, Guilhot F, et al. International randomized study of interferon vs. STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression of events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009;114:abstract 1126
   Web of Science ®Google Scholar
• Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006;354(19):2006-13
   PubMed Web of Science ®Google Scholar
• Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12(8):908-16
   PubMed Web of Science ®Google Scholar
• de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26(20):3358-63
   PubMed Web of Science ®Google Scholar
• Preudhomme C, Guilhot J, Nicolini FE, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010;363(26):2511-21
   PubMed Web of Science ®Google Scholar
• Cortes J, Quintas-Cardama A, Jones D, et al. Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. Cancer 2011;117(3):572-80
   PubMed Web of Science ®Google Scholar
• Cortes JE, Baccarani M, Guilhot F, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 2010;28(3):424-30
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004;103(8):2873-8
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian HM, Goldberg SL, et al. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. J Clin Oncol 2009;27(28):4754-9
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Lauseker M, Jung-Munkwitz S, et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011;29(12):1634-42
   PubMed Web of Science ®Google Scholar
• Alattar MKH, Jabbour E, et al. Clinical significance of complete cytogenetic response (CCyR) and major molecular response (MMR) achieved with different treatment modalities used as frontline therapy in chronic myeloid leukemia (CML) chronic phase (CP). Blood (ASH Annual Meeting Abstracts) 2011;118(21):abstract 745
   Google Scholar
• Hughes TP, Branford S, White DL, et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood 2008;112(10):3965-73
   PubMed Web of Science ®Google Scholar
• Keam SJ. Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. BioDrugs 2008;22(1):59-69
   Google Scholar
• Dasatinib: BMS 354825. Drugs RD 2006;7(2):129-32
   Google Scholar
• Jabbour E, Cortes J, Kantarjian H. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias. Expert Opin Invest Drugs 2007;16(5):679-87
   PubMed Web of Science ®Google Scholar
• Jabbour E, Jones D, Kantarjian HM, et al. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 2009;114(10):2037-43
   PubMed Web of Science ®Google Scholar
• Steinberg M. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther 2007;29(11):2289-308
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007;109(6):2303-9
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Pasquini R, Levy V, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009;115(18):4136-47
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007;109(12):5143-50
   PubMed Web of Science ®Google Scholar
• Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007;109(8):3207-13
   PubMed Web of Science ®Google Scholar
• Apperley JF, Cortes JE, Kim DW, et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. J Clin Oncol 2009;27(21):3472-9
   PubMed Web of Science ®Google Scholar
• Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 2007;109(10):4143-50
   PubMed Web of Science ®Google Scholar
• Shah NP, Kim DW, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010;95(2):232-40
   PubMed Web of Science ®Google Scholar
• Saglio G, Hochhaus A, Goh YT, et al. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer 2010;116(16):3852-61
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Cortes J, Kim DW, et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 2009;113(25):6322-9
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012;119(5):1123-9
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362(24):2260-70
   PubMed Web of Science ®Google Scholar
• Company BMS. Sprycel (dasatinib) [package insert]. Princeton, NJ: 2010
   Google Scholar
• Radich JP, Kopecky KJ, Appelbaum FR, et al. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood 2012;120(19):3898-905
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110(10):3540-6
   PubMed Web of Science ®Google Scholar
• le Coutre P, Ottmann OG, Giles F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008;111(4):1834-9
   PubMed Web of Science ®Google Scholar
• Le Coutre PD, Giles F, Hochhaus A, et al. Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: longer follow-up results of a phase II study [abstract]. J Clin Oncol 2009;27(Suppl 15):abstract 7057
   Google Scholar
• Hochhaus A, Giles FJ, Apperley J, et al. Nilotinib in Chronic Myeloid Leukemia Patients in Accelerated Phase (Cml-Ap) with imatinib resistance or intolerance: 24-month follow-up results of a phase 2 study [abstract 0631]. Haematologica 2009;94(Suppl2):256
   Google Scholar
• Giles FJ, Abruzzese E, Rosti G, et al. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia 2010;24(7):1299-301
   PubMed Web of Science ®Google Scholar
• Giles FJ, Kantarjian HM, le Coutre PD, et al. Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia 2012;26(5):959-62
   PubMed Web of Science ®Google Scholar
• Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362(24):2251-9
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011;12(9):841-51
   PubMed Web of Science ®Google Scholar
• Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012;26(10):2197-203
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Kim D-W, Issaragrisil S, et al. Enestnd 4-Year (y) update: continued superiority of nilotinib vs imatinib in patients (pts) with newly diagnosed Philadelphia chromosome-positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP). ASH Annu Meet Abstr 2012;120(21):1676
   Google Scholar
• Nicolini FE, Etienne G, Dubruille V, et al. Pegylated interferon-{alpha} 2a in combination to nilotinib as first line therapy in newly diagnosed chronic phase chronic myelogenous leukemia provides high rates of mr4.5. preliminary results of a phase II study. ASH Annu Meet Abstr 2012;120(21):166
   Google Scholar
• Ibrahim AR, Paliompeis C, Bua M, et al. Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy. Blood 2010;116(25):5497-500
   PubMed Web of Science ®Google Scholar
• Garg RJ, Kantarjian H, O'Brien S, et al. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood 2009;114(20):4361-8
   PubMed Web of Science ®Google Scholar
• Levinson NM, Boxer SG. Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain. PLoS One 2012;7(4):e29828
   PubMed Web of Science ®Google Scholar
• Remsing Rix LL, Rix U, Colinge J, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 2009;23(3):477-85
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian HM, Brummendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011;118(17):4567-76
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, KD, Turkina A, et al. Bosutinib (SKI-606) as second-line therapy for chronic phase chronic myeloid leukemia following imatinib failure: analyses of cross-intolerance and response by prior response to imatinib. 16th Congress of the European Hematology Association; 9–12 June 2011; London, UK
   Google Scholar
• Khoury HJ, Cortes JE, Kantarjian HM, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 2012;119(15):3403-12
   PubMed Web of Science ®Google Scholar
• Cortes JE, Maru A, Souza CAAD, et al. Bosutinib versus imatinib in newly diagnosed chronic phase chronic myeloid leukemia - BELA Trial: 24-month follow-up. ASH Annu Meet Abstr 2011;118(21):455
   Google Scholar
• O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009;16(5):401-12
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012;367(22):2075-88
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. A pivotal phase 2 trial of ponatinib in patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) resistant or intolerant to dasatinib or nilotinib, or with the T315I BCR-ABL mutation: 12-month follow-up of the PACE Trial. ASH Annu Meet Abstr 2012;120(21):163
   Google Scholar
• Yu Q, Eiring AM, Zabriskie MS, et al. Partially or fully BCR-ABL independent mechanisms of in vitro resistance to ponatinib. ASH Annu Meet Abstr 2011;118(21):2481
   Google Scholar
• Wetzler M, Segal D. Omacetaxine as an anticancer therapeutic: what is old is new again. Curr Pharm Des 2011;17(1):59-64
   Google Scholar
• Cortes-Franco J, Raghunadharao D, Parikh P, et al. Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in Chronic Myeloid Leukemia (CML) patients who are resistant or intolerant to two or more tyrosine kinase inhibitors - results of a multicenter phase 2/3 study. ASH Annu Meet Abstr 2009;114(22):861
   Google Scholar
• Cortes J, Lipton JH, Rea D, et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood 2012;120(13):2573-80
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Lipton JH, Baccarani M, et al. Long-term follow-up of ongoing patients in 2 studies of omacetaxine mepesuccinate for chronic myeloid leukemia. ASH Annu Meet Abstr 2012;120(21):2787
   Google Scholar
• Cortes JE, Nicolini FE, Wetzler M, et al. Subcutaneous omacetaxine in chronic or accelerated chronic myeloid leukemia resistant to two or more tyrosine-kinase inhibitors including imatinib. ASH Annu Meet Abstr 2011;118(21):3761
   Google Scholar
• Ayoubi M, Kantarjian HM, Wierda W, et al. A phase 2 study of the combination of omacetaxine and imatinib in the treatment of patients with Chronic Myeloid Leukemia (CML) in advanced stages or after failure to imatinib. ASH Annu Meet Abstr 2009;114(22):2193
   Google Scholar
• Kimura S, Naito H, Segawa H, et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005;106(12):3948-54
   Google Scholar
• Kantarjian H, le Coutre P, Cortes J, et al. Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. Cancer 2010;116(11):2665-72
   Web of Science ®Google Scholar
• Chan WW, Wise SC, Kaufman MD, et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell 2011;19(4):556-68
   PubMed Web of Science ®Google Scholar
• Cortes JE, Talpaz M, Kantarjian HM, et al. A phase 1 study of DCC-2036, a novel oral inhibitor of BCR-ABL kinase, in patients with Philadelphia chromosome positive (Ph+) leukemias including patients with T315I mutation. ASH Annu Meet Abstr 2011;118(21):601
   Google Scholar
• Shah NP, Kasap C, Paquette R, et al. Targeting drug-resistant CML and Ph+-ALL with the spectrum selective protein kinase inhibitor XL228. ASH Annu Meet Abstr 2007;110(11):474
   Google Scholar
• Cortes J, Paquette R, Talpaz M, et al. Preliminary clinical activity in a phase I trial of the BCR-ABL/IGF- 1R/aurora kinase inhibitor XL228 in patients with Ph++ leukemias with either failure to multiple TKI therapies or with T315I mutation. ASH Annu Meet Abstr 2008;112(11):3232
   Google Scholar
• Gontarewicz A, Brummendorf TH. Danusertib (formerly PHA-739358)–a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor. Recent Results Cancer Res 2010;184:199-214
   PubMedGoogle Scholar
• Bixby D, Talpaz M. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia 2011;25(1):7-22
   PubMed Web of Science ®Google Scholar
• Cortes-Franco J, Dombret H, Schafhausen P, et al. Danusertib hydrochloride (PHA-739358), a multi-kinase aurora inhibitor, elicits clinical benefit in advanced chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. ASH Annu Meet Abstr 2009;114(22):864
   Google Scholar
• Paquette RL, Shah NP, Sawyers CL, et al. PHA-739358, an Aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I mutations of BCR-ABL. ASH Annu Meet Abstr 2007;110(11):1030
   Google Scholar
• Foran JM, Ravandi F, O'Brien SM, et al. Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor, in patients with refractory leukemia. J Clin Oncol 2008;26(Suppl):abstract No. 2518
   Google Scholar
• Cortes J, Roboz GJ, Kantarjian HM, et al. A phase I dose escalation study of KW-2449, an oral multi-kinase inhibitor against FLT3, Abl, FGFR1 and aurora in patients with relapsed/refractory AML, ALL and MDS or resistant/intolerant CML. ASH Annu Meet Abstr 2008;112(11):2967
   Google Scholar
• Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11(11):1029-35
   PubMed Web of Science ®Google Scholar
• Legros L, Rousselot P, Giraudier S, et al. Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response. Blood 2012;120(9):1959-60
   Google Scholar
• Brave M, Goodman V, Kaminskas E, et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 2008;14(2):352-9
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Kim D-W, Pinilla-Ibarz J, et al. Efficacy and safety of ponatinib in patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-month follow-up of the PACE trial. ASH Annu Meet Abstr 2012;120(21):915
   Google Scholar